Arrowhead Pharmaceuticals Inc ARWR:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 3:29 PM EDT
48.43quote price arrow up+1.14 (+2.41%)
Volume
294,886
52 week range
26.81 - 84.83
Loading...
  • Open47.02
  • Day High48.44
  • Day Low46.50
  • Prev Close47.29
  • 52 Week High84.83
  • 52 Week High Date11/09/21
  • 52 Week Low26.81
  • 52 Week Low Date06/14/22

Key Stats

  • Market Cap5.126B
  • Shares Out105.85M
  • 10 Day Average Volume0.81M
  • Dividend-
  • Dividend Yield-
  • Beta1.39
  • YTD % Change-27.12

KEY STATS

  • Open47.02
  • Day High48.44
  • Day Low46.50
  • Prev Close47.29
  • 52 Week High84.83
  • 52 Week High Date11/09/21
  • 52 Week Low26.81
  • 52 Week Low Date06/14/22
  • Market Cap5.126B
  • Shares Out105.85M
  • 10 Day Average Volume0.81M
  • Dividend-
  • Dividend Yield-
  • Beta1.39
  • YTD % Change-27.12

RATIOS/PROFITABILITY

  • EPS (TTM)-1.48
  • P/E (TTM)-32.74
  • Fwd P/E (NTM)-21.32
  • EBITDA (TTM)-149.28M
  • ROE (TTM)-34.56%
  • Revenue (TTM)249.94M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-61.59%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date11/21/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Arrowhead Pharmaceuticals Inc

There is no recent news for this security.

Profile

MORE
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The...
Douglass Given M.D., Ph.D.
Chairman of the Board
Christopher Anzalone Ph.D.
President, Chief Executive Officer, Director
Patrick O'Brien J.D.
Chief Operating Officer, Chief Compliance Officer, General Counsel, Company Secretary
Kenneth Myszkowski
Chief Financial Officer
Address
177 E Colorado Blvd, Suite 700
Pasadena, CA
91105
United States

Top Peers

SYMBOLLASTCHG%CHG
ITCI
Intra-Cellular Therapies Inc
52.74-0.82-1.54%
GBT
Global Blood Therapeutics Inc
67.20+0.45+0.67%
BEAM
Beam Therapeutics Inc
70.57+1.49+2.16%
DNLI
Denali Therapeutics Inc
37.79-0.32-0.84%
NTLA
Intellia Therapeutics Inc
68.30+0.56+0.83%